A Stock Recent News

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable options income strategy. In this monthly series, we present how to go about selecting the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options, CALL options, and deep-in-the-money CALL options.

The company's top line has contracted in the recent past due to lower sales in China.

Agilent's (A) fourth-quarter fiscal 2023 results are hurt by weakness in the LSAG segment and softness in the China market.

Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended October 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Agilent Technologies, Inc. (NYSE:A ) Q4 2023 Earnings Conference Call November 20, 2023 4:30 PM ET Company Participants Parmeet Ahuja - IR Mike McMullen - President and CEO Robert McMahon - SVP and CFO Sam Raha - President, Agilent Diagnostics & Genomics Group Padraig McDonnell - President, Agilent CrossLab Group Phil Binns - President of the Agilent Life Sciences and Applied Markets Group Conference Call Participants Vijay Kumar - Evercore ISI Patrick Donnelly - Citigroup Inc. Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Josh Waldman - Cleveland Research Daniel Brennan - TD Cowen Dan Leonard - UBS Operator Ladies and gentlemen, welcome to the Agilent Technologies Q4 2023 Earnings Conference Call. My name is Bo and I will be coordinating your call today.

Agilent Technologies (NYSE:A) Inc after Monday's close announced fourth quarter 2023 financial results that exceeded expectations on both the top and bottom lines.  The analytical and clinical laboratory technologies provider's adjusted earnings per share (EPS) for the period declined 10% year over year to $1.38, while its revenue fell 9% to $1.69 billion.

In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, but also have potential for future growth.

Ari Wald, managing director and head of technical analysis at Oppenheimer, joins 'The Exchange' to discuss Medtronic, Agilent Technologies, and Trip.com.

Agilent Technologies (NYSE:A) has been downgraded from ‘Buy' to ‘Neutral' by UBS analysts who believe that the life sciences and diagnostics company's overexposure to regional headwinds in China, instrument demand normalization and softening cyclical spending could pressure forecasts. They highlighted that Agilent makes 20% of its sales in China but a lack of government stimulus, anti-corruption efforts, reshoring, and limited funding availability have pressured biopharma demand in the country.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 6th Annual Evercore ISI HealthCONx conference on Wednesday, Nov. 29, at 10:50 a.m. ET. A live webcast and audio archive of the virtual session will be available in the News and Events section of Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (N.